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InﬂammationSurfacen® is a clinical surfactant preparation of porcine origin. In the present study, we have evaluated the effect
of Surfacen® in the modulation of oxidative burst in monocytes and neutrophils in human blood and pro-
inﬂammatory cytokine production in peripheral blood mononuclear cells (PBMC). Reactive oxygen species
(ROS) level was measured in monocytes and neutrophils by ﬂow cytometry using 2,7-dichloroﬂuorescein
diacetate (DCFH-DA) as substrate, while, tumor necrosis factor (TNF)-α and interleukin (IL)-6 levels were
estimated in PBMC supernatant by enzyme-linked immunosorbent assays (ELISA). Our results show that
Staphylococcus aureus-induced ROS level was slightly affected by Surfacen® added to whole blood monocytes
and neutrophils. The time course experiments of pre-incubation with Surfacen® showed no signiﬁcant increase
of ROS level at 2 h; however, the ROS level decreased when pre incubated for 4 h and 6 h with Surfacen®. Pre-
incubation of PBMC cells with Surfacen® at 0.125 and 0.5 mg/mL showed a dose-dependent suppression of
TNF-α levels measured after 4 h of S. aureus stimulation, an effect less impressive when cells were stimulated
for 24 h. A similar behavior was observed in IL-6 release. In summary, the present study provides experimental
evidence supporting an anti-inﬂammatory role of Surfacen® in human monocytes and neutrophils in vitro.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The pulmonary surfactant is a complexmixture of lipids and proteins.
It is synthesized by alveolar type II epithelial cells into alveolar space. The
main functions of pulmonary surfactant include (i) reducing the surface
tension at the air–liquid interface of the alveolus, (ii) avoiding the alve-
olar collapse, and, (iii) reducing the work of breathing [1]. Besides
these properties, pulmonary surfactant also play a major role in the pul-
monary defense through preventing the access of pathogens at the large
alveolar surface exposed to the environment; there is growing evidence
that pulmonary surfactant has a potential role in modulating inﬂamma-
tion in normal and injured lungs [2]. Pulmonary surfactant has been used
to treat Neonatal Respiratory Distress Syndrome (NRDS), with improve-
ment in morbidity and mortality in very low birth weight babies [3,4].
Surfacen® is a clinical surfactant preparation of porcine origin which is
widely used in Cuba to treat pre-term babies at risk or already suffering
Neonatal Respiratory Distress [5,6].a, EPM, UNIFESP, Rua Pedro deThe potential use of surfactant preparations in other diseases such as
Acute Lung Injury (ALI) and its severe form Acute Respiratory Distress
Syndrome (ARDS) demands the evaluation of its immunomodulatory
properties. ALI or ARDS is a life-threatening condition that is character-
ized by increased inﬂammatory cytokine levels and cell inﬁltration into
the lungs, non-cardiogenic pulmonary edema, and diffuse alveolar dam-
age that culminates in respiratory failure [7,8]. Neutrophils play a key
role in the immune defense against invading microbes. These cells can
readily move to the inﬂammatory sites by chemotaxis, phagocytize
the microbes and release reactive oxygen metabolites or enzymes for
bacterial death [9]. Staphylococcus aureus (S. aureus) remains a major
cause of human infections, and the arising of highly virulent, drug-
resistant strains has made treatment more difﬁcult [10]. It is also
known to be one of the pathogens responsible for sepsis-induced ALI/
ARDS [11].
The inﬂammatory response is fundamental for the control of infec-
tion, but also underscores the pathophysiologic events of organ dys-
function in sepsis [12]. The regulation of mediators released from cells
within the alveolar space would represent a desirable effect of surfac-
tants. Within the alveolar space, resident macrophages are constantly
bathed in the phospholipid-rich surfactant; regulatory effects are
Fig. 1. Production of ROS by whole bloodmonocytes and neutrophils from healthy volun-
teers (n = 7) in different conditions: control and after S. aureus stimuli without or with
simultaneously added Surfacen® (0.125, 0.25 and 0.5 mg/mL). The monocytes and
neutrophils were characterized by side-scatter and forward scatter parameters and
positive staining for CD14 and CD15 respectively. ROS generations are expressed as the
geometric mean of ﬂuorescence intensity (GMFI) ± standard error. * p ≤ 0.05 S. aureus
compared to control in monocytes and neutrophils; + p ≤ 0.05 S. aureus + Surfacen®
0.5 mg/mL compared to S. aureus in neutrophils.
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ﬂammatory damage. In the present study, we evaluated the effects of
a clinical surfactant preparation, Surfacen®, in themodulation of oxida-
tive burst and pro-inﬂammatory cytokine production induced by a bac-
terial stimulus in monocytes and neutrophils in peripheral human
blood.
2. Materials and methods
2.1. Drug
The Surfacen® preparation was provided by the Centro Nacional de
Sanidad Agropecuaria (CENSA, Mayabeque, Cuba). Surfacen® is obtain-
ed from organic extracts of porcine bronchoalveolar lavages, which
are subjected to acetone precipitation to reduce their content of
neutral lipids. This surfactant contains about 95% polar lipids, mainly
dipalmitoylphosphatidylcholine (DPPC), and 1% hydrophobic proteins
(SP-B and SP-C). It is provided as a sterile white lyophilized powder,
in 50mg phospholipids vials [13]. To reconstitute Surfacen®, the appro-
priate amount of the surfactant is weighted and resuspended in sterile
distilled water. For experiment of oxidative burst and cytokines
modulation, surfactant was used at the concentrations from 0.125 to
0.5 mg/mL.
2.2. Healthy volunteers
Blood samples from 13 healthy volunteers (mean age, 37.4 ±
10.2 years; 69% females) were drawn into heparin-treated vacuum
tubes (Becton Dickinson, UK). All volunteers agreed to participate and
reported being healthy without medication.
2.3. Analysis of oxidative burst production in whole blood after stimulation
with S. aureus
The oxidative burst production was quantiﬁed in monocytes and
neutrophils in whole blood by measuring the oxidation of 2,7-
dichloroﬂuorescein diacetate (DCFH-DA; Sigma, St. Louis, MO) as de-
scribed previously [14]. In brief, ROS were measured constitutively
and after stimulation with S. aureus (ATCC 25923; Difco, Detroit, MI)
at 2.4 × 108 colonies/mL [15]. The whole blood was pre-incubated
with Surfacen® for 0, 60, 120, 240 and 360min at 37 °C and 5% CO2 be-
fore adding S. aureus. Sampleswere further incubated in the presence of
0.3 mMDCFH-DA in a 37 °C shakingwater bath for 30min. After the in-
cubation, 2 mL of 3 mM EDTA (Sigma) was added to each tube and the
mixture was then centrifuged (652 ×g for 5 min at 4 °C). Hypotonic
lyses in 0.2% saline was followed by the addition of 1.6% saline and
centrifugation (652 ×g for 5 min at 4 °C). The supernatants were
discarded, and the pellets were incubated with 5 μL of CD14-
peridinin-chlorophyll-protein monoclonal antibody (PerCP;) and 5 μL
of CD15 allophycocyanin (APC; both antibodies from BD Biosciences,
San Jose, CA) at room temperature for 15min in the dark. Twomilliliters
of PBS was then added to each tube, and the mixture was centrifuged
(652 ×g for 5 min at 4 °C). The supernatants were discarded, and the
pellets were resuspended in 250 μL of 3 mM EDTA in PBS for ROS
determination.
Neutrophils were characterized in whole blood by side-scatter and
forward scatter parameters, and positive staining for CD15; monocytes
were characterized by side-scatter and forward-scatter parameters
and positive staining for CD14. ROS generation is expressed as the geo-
metric mean of ﬂuorescence intensity (GMFI).
2.4. Induction of cytokines in peripheral blood mononuclear cells (PBMC)
PBMCs were collected by the Ficoll density gradient method (Ficoll-
Paque plus, AmershamBioscience GEHealthcare, Uppsala, Sweden) and
suspended in RPMI 1640 medium (Sigma) supplemented with 10%fetal calf serum, 10 IU/mL penicillin, 10 μg/mL streptomycin (Gibco,
Gaisthersburg, MD), and 200 mM L-glutamine (Sigma), adjusted to a
concentration of 2 × 106 cells/mL. The cell viability and count were
made with trypan blue dye using a hemocytometer chamber. After
preliminary dose–response experiments (data not shown), cells were
pre-incubated with Surfacen® for 0, 60, 120, 240 and 360 min and
then stimulated with 4.8 × 107 colonies/mL of S. aureus for 4 and 24 h
at 37 °C with 5% CO2. Cells without stimulus were used to measure the
unspeciﬁc stimulation. Supernatants were collected after 4 or 24 h of in-
cubation, by centrifugation the samples at 805 ×g for 5min at 4 °C. Cell-
free supernatants were stored in aliquots at−80 °C until used for cyto-
kine determination.
2.5. Measurement of cytokines
The TNF-α and IL-6 were measured by capture enzyme-linked im-
munosorbent assays (ELISA) according to the manufacturer's instruc-
tions. Antibody pairs and reagents (OptEIA sets) were obtained from
BD Biosciencies. Samples were tested in duplicates, and a standard
curve with human recombinant cytokine was prepared in each plate.
Sensitivity was 10 pg/mL for both cytokines measured.
2.6. Statistical analysis
Statistical analyses were performed using SPSS 21.0 software. Data
were expressed as mean ± SEM and analyzed with one way ANOVA
with a LSD post hoc test. A probability value of p≤ 0.05 was considered
statistically signiﬁcant.
3. Results
3.1. Effect of pulmonary surfactant on ROS production in monocytes and
neutrophils of human blood
Un-stimulated monocytes and neutrophils did not show any signiﬁ-
cant changes in ROS levels with the concentrations of 0.125, 0.25 and
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showed signiﬁcant increase of ROS levels (135.5 ± 48.3 and 140.7 ±
37.0 GMFI respectively) after stimulation of S. aureus. It is also observed
that Surfacen® did not induce ROS in the S. aureus stimulated cells in
low concentrations (0.125 and 0.25 mg/mL),while, neutrophils showed
signiﬁcant changes in ROS level with 0.5 mg/mL of Surfacen® (Fig. 1).
The time course experiments of pre-incubation with Surfacen®
showed a biphasic effect on S. aureus-induced ROS generation in
monocytes (Fig. 2A), with a slight and non signiﬁcant increase until
2 h of pre-incubation, followed by a decreased ROS generation after
4 and 6 h of Surfacen® pre-incubation (Fig. 2A). The same trend
was found in neutrophils (Fig. 2B).
3.2. Effect of Surfacen® on TNF-α and IL-6 release by PBMCs stimulated
with S. aureus
TNF-α secretions were measured after 4 and 24 h in unstimulated
and S. aureus-stimulated PBMCswith Surfacen®. In the absence of stim-
ulus low levels of TNF-α were detectable, which were not affected by
surfactant. Stimulation with 4.8 × 107 colonies/mL of S. aureus resultedFig. 2. Time course of ROS production by monocytes (A) and neutrophils (B) in response to pre
terized by side-scatter and forward scatter parameters and positive staining for CD14 and CD15
(GMFI) ± SE. Samples from 3 to 12 healthy volunteers were used in each time point. Differentin TNF-α release after 4 h that was fourfold (1167 ± 539.2 pg/mL) the
basal production (273.9 ± 106 pg/mL) of TNF-α, with sustained levels
until 24 h (1064.2 ± 929.4 pg/mL) of incubation. A dose-dependent
suppression of TNF-α release was observed when PBMCs were pre-
incubated with different concentrations of Surfacen® and challenged
with S. aureus for 4 h (Fig. 3A). The level of TNF-α decreased up to
60% in S. aureus-induced cells when pre incubated with Surfacen® for
4 h (Fig. 3A). When cells were stimulated for 24 h, the reduction of
TNF-α supernatant's levels was less impressive, with a signiﬁcant de-
crease observed only with the higher concentration of Surfacen®
(Fig. 3B).
Similarly, the level of IL 6wasminimal with andwithout surfactant in
unstimulated cells. In contrast, the level of IL 6 increased up to two fold
(16399 ± 9719.3 pg/mL) after 2 h and ﬁvefold (51180.8 ±36075.9 pg/
mL) after 24 h in S. aureus stimulated cells (4.8 × 107 colonies/mL)
when compared with normal (8684.4 ± 5122.7 pg/mL).
A dose dependent suppression of IL-6 levels detected after 4 h of
S. aureus stimulation was observed with pre incubation of Surfacen®
in PBMCs (p ≤ 0.05) (Fig. 3C). When cells were stimulated for 4 h,
Surfacen®, at a concentration of 0.5 mg/mL, induced about 40%-incubation with Surfacen® in whole blood. The monocytes and neutrophils were charac-
respectively. ROS generation is expressed as the geometric mean of ﬂuorescence intensity
letters means signiﬁcant difference between the groups (p ≤ 0.05) in each time point.
Fig. 3. Surfacen®modulation of S. aureus-induced TNF-α and IL-6 production by PBMC. PBMCswere pre-incubatedwith Surfacen® for different time points and stimulatedwith S. aureus
for 4 and24h.Values of TNF-α (A andB) and IL-6 (C andD) for 4 health volunteer are expressed as thepercentage of cytokines levels produced inpresence of S. aureus alone (% S. aureus) in
function of time of pre-incubation. *p ≤ 0.05 cells pre-incubated with Surfacen® and stimulated with S. aureus compared to cell stimulated with S. aureus alone, +p ≤ 0.05 between
S. aureus+ Surfacen® 0.5 mg/mL after 60 minutes compared to 240 min.
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to 6 h of pre-incubation,with the higher inhibition observed at 4 h. Sim-
ilar to TNF-α, no signiﬁcant changes were observed in IL-6 production
with 0.125 mg/mL of Surfacen®; however, signiﬁcant reduction ob-
served with Surfacen® 0.5 mg/mL after 24 h of stimulation (Fig. 3D).
4. Discussion
Phagocytes, particularly macrophages and polymorphonuclear
(PMN) cells, are recognized as the main components of the cellular im-
mune and inﬂammatory response in the lung [16,17]. S. aureus stimu-
lates alveolar macrophages to produce inﬂammatory cytokines and
free oxygen radicals, which can damage the lungs. S. aureus has been
isolated frombronchoalveolar lavage in patientswithARDS [11]. Our re-
sults showed that surfactant inhibits TNF-α and IL-6 induced by
S. aureus in mononuclear cells in vitro. The modulation of ROS genera-
tion was less impressive, yet a biphasic effect might be envisaged with
increasing pre-incubation periods.
The effect of pulmonary surfactant preparations in the production of
ROS has been studied and conﬂicting results have been obtained
[18–20]. The surfactant effect in the production of ROS is determined,
among other factors, by the dose and type of surfactant, type of stimu-
lus, variations in interspecies or cell type, or differences in experimental
conditions [21]. Our results usingwhole blood stimulatedwith S. aureus
to induce ROS production suggest that Surfacen® has little effect in the
production of ROS, when added simultaneously with the stimulus. This
ﬁnding is in agreement with previously reported studies showing no
surfactant modulation of PMN stimulated by opsonized group B strep-
tococci [22] or monocytes stimulated by phorbol 12-myristate 13-
acetate (PMA) and opsonized zymosan [19]. Individual surfactantphospholipids differently modulate priming of macrophages for oxida-
tive responses, and the effect of individual phospholipids does not ac-
count for the effect of complete pulmonary surfactant on priming of
macrophages. Also, the effects of phospholipids on oxidative responses
of macrophages are different when elicited with PMA or Op-Zym [23].
Curosurf® (Chiesi Farmaceutici, Parma, Italy) did not affect the PMA-
induced superoxide anion production; however, pre-incubation with
Curosurf® caused a signiﬁcant inhibition of the OM-85-induced super-
oxide anion production [21]. Survanta®(Abbott Laboratories, Abbott
Park, IL) and Alveofact® (Boehringer Ingelheim Co., Ingelheim,
Germany), other clinical surfactant preparations, stimulated the oxygen
metabolite release from PMN incubated with E. coli and S. aureus re-
spectively; however, these effects did not reach statistical signiﬁcance
[24].
More recently, three clinical surfactants were evaluated against ROS
production. At low concentrations these surfactants did not inﬂuence
the production of ROS stimulated by PMA, while at higher concentra-
tions, all surfactant preparations tested signiﬁcantly reduced ROS
production. These authors also studied the effect of DPPC on ROS pro-
duction, and revealed an inhibitory effect [25]. In general some of the
observed differences mentioned above might be explained by the use
of different stimulants (e.g. PMA or bacteria), as it has been demonstrat-
ed that PMA and bacterial induced oxygen metabolite release are regu-
lated by different mechanisms [9].
Furthermore, the dose of phospholipids and the time of incubation
have a critical impact on oxidative functions. Phosphatidylcholine
arachidonoyl-palmitoyl (PAPC) showed a stimulatory or inhibitory
response in the respiratory burst which depends on lipid dose and
time of incubation [26]. Our results also suggested a time dependent
changes in ROS generation with pre-incubated surfactant. The clinical
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are not clear, contrasting with the potential beneﬁts of inhibiting in-
ﬂammatory cytokines.
Although the effect of surfactant preparations modulating ROS pro-
duction has been controversial, their inhibitory effect on proinﬂamma-
tory cytokines seems to be consensus.
Our results conﬁrmed previous reports with other clinical surfac-
tants, that is, Surfacen® is also able to inhibit the production of TNF-α
and IL-6. Studies have been conducted to investigate the kinetics of cy-
tokines in animal models of acute lung injury [27–29]. TNF-α and IL-6,
among other mediators, were demonstrated in lung tissues as well as
in alveolar macrophages and polymorphonuclear cells from bronchoal-
veolar lavage of animals with acute lung inﬂammation induced by lipo-
polysaccharide or bacteria.
Several of the surfactants used as replacement therapy showed an
inhibitory effect on cytokine release in patients with NRDS. Curosurf®
inhibited the secretion of TNF-α in monocytes [19], while Survanta®
and Exosurf® (Burroughs Wellcome, Research Triangle Park, NC)
inhibited the production of IL-1 β, pro-IL-1 β and TNFα in alveolarmac-
rophages stimulatedwith LPS [30]. These results showed that a synthet-
ic surfactant (Exosurf®) as well as an exogenous bovine natural
surfactant (Survanta®), containing hydrophobic proteins (SP-B and
SP-C) has a cytokine inhibitory effect.
Both Survanta® and Exosurf® exert inhibitory effect by decreasing
activation of the nuclear factor (NF)-κB in one human monocytic cell
line [31]. It has also been demonstrated that exogenous porcine natural
surfactant, Curosurf® affects TNF-α release of LPS-stimulated
monocytes at a pretranslational level by down-regulating both mRNA
for TNF-α and TNF-α-Receptor II, therefore acting as an anti-
inﬂammatory agentwithin alveolar space [32]. Other studies have dem-
onstrated that surfactant suppressed NF- κB transcriptional activation
and translocation to the nucleus and signiﬁcantly inhibited IκB phos-
phorylation and degradation by blocking IKKa kinase expression in the
lung tissue [33].
Several studies revealed themechanismand effects of phospholipids
and their function in host defense. Total phosphatidylcholine (tPC; het-
erogeneous species of PC fromegg) andDPPC, but not the PC 16/20:4 in-
hibit the release of TNF α in a monocyte cell line, suggesting that the
mechanism by which this effect is exerted is by altering the ﬂuidity of
the membrane [26]. Also, the DPPC can inhibit LPS-stimulated PAF pro-
duction via perturbation of the cell membrane, which inhibits the activ-
ity of speciﬁc membrane-associated enzymes involved in PAF
biosynthesis [34]. Studies have demonstrated that the SP-C, when com-
bined with DPPC vesicles, is capable of inhibiting the binding of LPS on
RAW 264.7 macrophages and therefore inhibited both nitric oxide pro-
duction and TNF-α in peritoneal and alveolar macrophages [35]. The
surfactant anionic phospholipids have an important role in suppressing
inﬂammation within the alveolar compartment in the lung [36]. It sig-
niﬁcantly inhibits the production of TNF α and nitric oxide induced by
LPS in alveolar macrophages and reduces phosphorylation of multiple
intracellular protein kinases. At the same time the anionic phospho-
lipids were also effective in attenuating inﬂammation when adminis-
tered intratracheally to mice challenged with LPS. Palmitoyl oleoyl
phosphatidylglycerol (POPG) has a direct action on the attenuation of
the LPS-induced inﬂammatory response by inhibiting the production
of IL-6 and IL-8 in respiratory tract infections such as Respiratory Syncy-
tial Virus, indicating that the administration of speciﬁc phospholipids
can be utilized in the prevention and treatment of respiratory disease
[37]. Surfacen® is characterized by the highest content of PG and also
by the higher content of anionic phospholipids in their biochemical
composition in comparisonwith other clinical surfactants [38]. This fea-
ture allows a preparation Surfacen® to be a successful candidate in the
treatment of ALI/ARDS.
In summary, the present study provides experimental evidence in
favor of an anti-inﬂammatory role of Surfacen® in human monocytes
and neutrophils in vitro.Acknowledgments
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